SCHEMBL22309461

SCHEMBL22309461

c1ccc(-c2ccc(-c3nc(-c4ccccc4)nc(-c4cccc(-c5cccc(-c6cc(-c7ccccc7)nc(-c7ccc8c(c7)oc7ccccc78)n6)c5)c4)n3)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.50
KMT2A Q03164 9/20 0.50
MAPT P10636 7/20 0.50
ALDH1A1 P00352 6/20 0.50
HPGD P15428 6/20 0.50
KDM4E B2RXH2 4/20 0.50
LMNA P02545 2/20 0.50
GLA P06280 1/20 0.50
NTSR1 P30989 1/20 0.45
HCRTR1 O43613 1/20 0.42
PLA2G2A P14555 3/20 0.42
PLA2G4A P47712 3/20 0.42
MMP12 P39900 1/20 0.41
MMP13 P45452 1/20 0.41
AHR P35869 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
PLA2G10 O15496 1/20 0.39
MAOA P21397 2/20 0.39
MAOB P27338 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22309611 1.00 MEN1 (0.50) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL22309296 1.00 MEN1 (0.50) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL22310003 1.00 MEN1 (0.50) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL21023970 1.00 MEN1 (0.50) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL22308950 1.00 MEN1 (0.50) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL22309464 1.00 MEN1 (0.50) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL21140063 1.00 MEN1 (0.50) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL22308644 1.00 MEN1 (0.50) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL22308642 1.00 MEN1 (0.50) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL22309485 1.00 MEN1 (0.50) MEN1KMT2AMAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11917910-B2 Organic compound and organic electroluminescent device using the same SOLUS ADVANCED MATERIALS CO., LTD. (KR) 2024-02-27 US disclosed
US-11917910-B2 Organic compound and organic electroluminescent device using the same SOLUS ADVANCED MATERIALS CO., LTD. (KR) 2024-02-27 US disclosed
US-20200251659-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME DOOSAN CORPORATION (KR) 2020-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200251659-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME VDAC1, OR10J3, PIEZO1 MEN1 2484/4885KMT2A 2549/4885MAPT 660/4885
US-11917910-B2 Organic compound and organic electroluminescent device using the same VDAC1, OR10J3, PIEZO1 MEN1 2484/4885KMT2A 2549/4885MAPT 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.